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Study Visits and Metabolic Testing 
Body composition analyses, assessment of resting energy expenditure, a three-stage, 
hyperinsulinemic-euglycemic pancreatic clamp procedure, a mixed-meal metabolic test, and a 24-hour 
assessment of plasma glucose, insulin and c-peptide concentration profiles were conducted in the 
Clinical and Translational Research Unit and the Center for Clinical Imaging Research at Washington 
University School of Medicine before and after participants achieved a targeted (~18%) weight loss. All 
inpatient testing occurred during two study visits, approximately 1-2 weeks apart. Assessment of resting 
energy expenditure and the clamp procedure were conducted during the first inpatient admission to the 
research unit, and the mixed-meal metabolic test plus 24-hour assessment of plasma substrates and 
hormones were conducted during the second inpatient admission to the research unit. In addition, fecal 
samples were collected from each subject before and after weight loss. 
Body Composition 
Body fat mass and fat-free mass were determined by using dual-energy X-ray absorptiometry, 
and intra-abdominal adipose tissue volume and intrahepatic triglyceride content were determined by 
using magnetic resonance spectroscopy.1  
Dual Glucose Tracer Mixed-meal Metabolic Test and 24-hour Blood Sampling 
Participants were admitted to the Washington University Clinical and Translational Research 
Unit in the afternoon and consumed a standard evening meal containing 50% of calories as 
carbohydrate, 30% as fat, and 20% as protein. In the morning, after participants had fasted overnight, a 
catheter was inserted into a forearm vein for infusion, and a second catheter was inserted into a radial 
artery to obtain arterial blood samples. At 0600 h, a primed, continuous infusion of [6,6-2H2]glucose 
(priming dose, 22.5 µmol/kg; infusion rate, 0.25 µmol/kg/min) was started and continued until 1300 h. At 
0900 h, after 3 hours of tracer infusion, participants ingested a 450 kcal liquid meal, containing 49 g of 
glucose mixed with 0.9 g [U-13C]glucose, 18 g of fat, and 22 g of protein, which was provided in 7 
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equally divided aliquots given every 5 minutes for 30 minutes (0900-0930 h). Blood samples were 
collected immediately before starting the glucose tracer infusion, before initiating meal ingestion (times 
-20, -10 and 0 minutes), every 10 minutes for the first 60 minutes, and then every 20 minutes for the 
remaining 3 hours to determine plasma substrate, hormone concentrations, and glucose tracer-to-
tracee ratios. After completing the mixed meal metabolic test, participants remained in the Clinical and 
Translational Research Unit until 0900 h the next day to complete the remainder of the 24-hour 
metabolic study. Liquid meals containing 50% carbohydrate, 35% fat, and 15% protein were provided at 
1300 h, 1700 h, and 2100 h, which were consumed in seven equally divided aliquots every 5 minutes 
for 30 minutes. The energy content of the meal was individualized based on each subject’s estimated 
total daily energy requirement, calculated as 1.25 times measured resting energy expenditure assessed 
by using a metabolic cart (TrueOne 2400, ParvoMedics, Sandy, UT). Blood samples were obtained 
every hour from 1300 h to 0100 h and then every 2 hours from 0100 h until 0900 h the next morning to 
determine plasma glucose, free fatty acid, insulin and C-peptide concentrations. 
Hyperinsulinemic-euglycemic Pancreatic Clamp Procedure  
Participants were admitted to the Clinical and Translational Research Unit in the afternoon and 
consumed a standard evening meal, containing 50% of calories as carbohydrate, 30% as fat, and 20% 
as protein. The following morning, after participants had fasted for about 10 h overnight, a catheter was 
inserted into a forearm vein for infusion, and a second catheter was inserted into a radial artery to 
obtain arterial blood samples. At 0600 h, a 9-h three-stage hyperinsulinemic-euglycemic pancreatic 
clamp procedure was started by infusing octreotide (45 ng/kg fat free mass/min) and replacement 
doses of glucagon (1.5 ng/kg fat free mass/min) and growth hormone (6 ng/kg fat free mass/min), 
which were maintained until the end of the study (a diagram below describes the stages of the clamp 
procedure). An intravenous infusion of insulin was started at 0600 h at a rate of 15 mU/m2 body surface 
area/min (stage 1) for 3 hours (initiated with an insulin infusion of 60 mU/m2 body surface area/min for 5 
minutes and then 30 mU/m2 body surface area/min for 5 minutes), and was increased to 25 mU/m2 
5 
 
body surface area/min (stage 2) for the next 3 hours (initiated with an insulin infusion of 100 mU/m2 
body surface area/min for 5 minutes and then 50 mU/m2 body surface area/min for 5 minutes), and 
then increased to 50 mU/m2 body surface area/min (stage 3) for the final 3 hours (initiated with an 
insulin infusion of 200 mU/m2 body surface area/min for 5 minutes and then 100 mU/m2 body surface 
area/min for 5 minutes).  A primed, constant infusion of [6,6-2H2]glucose (priming dose 22.5 µmol/kg 
body weight and 0.25 µmol/kg body weight/min infusion) was started at 0600 h, followed by an infusion 
of [U-13C]palmitate (6 nmol/kg fat free mass/min) at 0700 h. The infusion rate of [6,6-2H2]glucose and 
[U-13C]palmitate was reduced by 50% and 75% during stages 2 and 3 of the hyperinsulinemic-
euglycemic pancreatic clamp procedure, respectively, to account for the expected decrease in 
endogenous glucose production and adipose tissue lipolytic rates. Plasma glucose concentration was 
kept constant during stages 1 and 2 and maintained at ~100 mg/dL during stage 3 of the clamp 
procedure by infusing 20% dextrose enriched to 2% with [6,6-2H2]glucose.  
Plasma glucose and insulin concentrations achieved during each stage of the clamp procedure 
conducted after weight loss were purposely controlled to match the values obtained before weight loss 
in both the Diet and Surgery groups. Blood samples were collected immediately before starting the 
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glucose tracer infusion, and every 10 min during the final 20 minutes (3 samples) of each stage of the 
clamp procedure to determine plasma glucose and insulin concentrations, and both glucose and 
palmitate tracer-to-tracee ratios. The assessment of hepatic and adipose tissue insulin sensitivity was 
performed during low-dose (15 mU/m2 body surface area/min) and medium-dose (25 mU/m2 body 
surface area/min) insulin infusion to submaximally suppress glucose production and lipolysis. The 
assessment of skeletal muscle insulin sensitivity was performed during high-dose (50 mU/m2 body 
surface area/min) insulin infusion to adequately stimulate glucose disposal.2  Resting energy 
expenditure was determined by a metabolic cart with online expiratory gas exchange analysis (TruOne 
2400; ParvoMedics, Sandy, UT) from 0630 h to 0700h during the clamp procedure.3 
Weight Loss Interventions 
Diet group. Participants in the Diet group received weekly individual dietary and behavioral 
education sessions during the entire study period. All meals were provided to participants as liquid 
shakes (Optifast HP® Shake Mix, Fremont, MI) and prepackaged entrees (30% carbohydrate; 40% 
protein; 30% fat; 200 kcal/meal) prepared by the Clinical and Translational Research Unit Metabolic 
Kitchen to enhance compliance with low-calorie dietary therapy. Participants were instructed to keep 
daily food records and enter their data into the MyFitnessPal application (MyFitnessPal, Inc). Food 
records were evaluated by the study dietitian and behavioral psychologist, and the daily energy content 
of the meals was adjusted weekly as needed to achieve about a 1% decrease in body weight per week. 
After participants achieved about an 18% weight loss, energy intake was adjusted to prevent continued 
weight loss and maintain a stable body weight (<2% change) for 3 weeks before repeat testing was 
performed at 23±7 weeks after starting diet therapy.  
Surgery group. The gastric bypass procedure was performed by using standard laparoscopic 
techniques.4 A linear stapler was used to completely divide the stomach into a small (15-20 ml) 
proximal gastric pouch and a large distal gastric remnant. A Roux limb was constructed by transecting 
the jejunum 30-50 cm distal to the ligament of Treitz. The proximal cut end of the jejunum 
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(biliopancreatic limb) was anastomosed 75 -150 cm distally on the Roux limb by using a linear 
stapler.  The proximal end of the Roux limb was anastomosed to the proximal gastric pouch by using a 
stapled technique.  The first week after surgery participants consumed a liquid diet only. Progression to 
regular foods occurred 2-4 weeks after surgery. A study dietitian consulted with participants weekly by 
phone or in person to monitor body weight, review dietary intake and adjust dietary intake in order to 
meet the targeted weight loss goal. After participants achieved about an 18% weight loss, energy intake 
was adjusted to prevent continued weight loss and maintain a stable body weight (<2% change) for 3 
weeks before repeat testing was performed at 16±4 weeks after gastric bypass surgery.  
Management of Blood Glucose and Diabetes Medications 
Participants were provided with a glucometer and glucose test strips at the time of study 
enrollment and checked their blood glucose concentrations twice daily (before breakfast and before 
bedtime) by fingerstick throughout the study. Participants were instructed to stop taking oral and 
injectable diabetes medications at different time points before each admission to the Clinical and 
Translational Research Unit. Oral diabetes medications were discontinued 3 days before and insulin 
was discontinued 1 day before each admission, whereas glucagon-like peptide 1 receptor agonists 
were discontinued 2 weeks before the first admission and not restarted unless needed for glycemic 
control after second research unit admission.  During the period of medication withdrawal, blood 
glucose values obtained at home were reviewed regularly by the study physician. Participants were 
instructed to contact study medical staff when blood glucose was >200 mg/dl before breakfast or >300 
mg/dl before bedtime to obtain instructions for possible additional medical therapy. Blood glucose 
values were reviewed weekly throughout the study by the study nurse and physicians, and diabetes 
medications were adjusted every 1-2 weeks, as needed.   
Sample Analyses 
Blood samples. Plasma glucose concentrations were determined by using an automated 
glucose analyzer (YSI 2300 STAT plus; Yellow Spring Instrument Co, Yellow Springs, OH) and both 
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plasma insulin and c-peptide concentrations were determined by using electrochemiluminescence 
technology (Elecsys 2010, Roche Diagnostics). Plasma concentrations of leptin and high-molecular 
weight adiponectin were measured by using a commercially available radioimmunoassay kit (EMD 
Millipore, Burlington, MA) and enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, 
Minneapolis, MN), respectively. Plasma free fatty acid concentrations were measured by using a 
commercially available diagnostic kit (FUJIFILM Wako Diagnostics, Mountain View, CA). Plasma 
branched-chain amino acids (valine, leucine, and isoleucine) and short-chain acylcarnitines (propionyl 
carnitine [C3] and 2-methylbutyryl/isovaleryl carnitine [C5]) were analyzed by using liquid 
chromatography tandem mass spectrometry (LC-MS/MS). These metabolites were chromatographically 
separated by using a Thermo Vanquish UPLC system with a Zic-pHILIC (2.1 x 150 mm) 5µm column, 
and mass spectra acquired on a Thermo QExactive orbitrap mass spectrometer, as previously 
described.5 Metabolites were identified by matching accurate mass, retention time, and MS/MS 
fragmentation patterns to an in-house library of commercially available standards. Plasma bile acids 
concentrations were analyzed by adding isotopically labeled internal standards and using LC-MS/MS 
as previously described.6 Plasma glucose and palmitate tracer-to-tracee ratios were determined by 
using gas chromatography-mass spectrometry.7  
Fecal samples. DNA extraction, amplification of the V4 region of the 16S rRNA gene, and 
Illumina amplicon sequencing were performed at the University of California San Diego Center for 
Microbiome Innovation, according to the Earth Microbiome Project protocols.8 Sequence data were 
processed by using Quantitative Insights Into Microbial Ecology29 and sequences were deposited in the 
European Nucleotide Archive maintained at the European Bioinformatics Institute EBI-ENA (accession 
number EBI: ERP119960). Microbial sub-Operational Taxonomic Units were identified from sequences 
trimmed to 150 nucleotides by using the Deblur algorithm.10 Taxonomic assignment was performed with 
the GreenGenes v13.8 99% taxonomic reference database using the naïve Bayes classifier 
implemented in the q2-feature-classifier plugin,11 and bespoke taxonomic weights were provided to the 
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classifier by using the precompiled GreenGenes v13.8 V4 human-stool weights produced by the q2-
clawback plugin.12  
Beta diversity was calculated based on the sub-Operational Taxonomic Units relative 
abundance table by using the Bray-Curtis dissimilarity. Differential abundance testing was performed 
separately for each taxonomic level on features detected in at least 30% of samples with a mean 
relative abundance of 0.01%13 across all samples. Raw counts were modelled by using a negative 
binomial generalized linear model with sequencing depth as an offset. To analyze the within-subject 
change between groups by using fixed effects, a nested interaction formula was used with participant 
and time nested within treatment groups, and a custom contrast was specified to test the difference in 
the within-group change i.e. the group by time interaction. Means and 95% confidence intervals were 
estimated for the within-group differences at the phylum level. P-values were calculated for the group 
by time interaction at the genus level, and were adjusted for multiple comparisons by using the 
Benjamini-Hochberg false discovery rate and a 5% false discovery rate was considered statistically 
significant. Statistical analyses were performed by using R (The R Foundation for Statistical Computing, 
Vienna, Austria). 
Calculations 
Diabetes medication score. A diabetes medication score for each subject was calculated based 
on the number and dose of diabetes medications being taken, as described previously.14  For each 
medication, with the exception of insulin, a numerical score was calculated as the daily dose relative to 
the maximum recommended dose. For insulin, a numerical score was calculated as the daily insulin 
dose relative to a standard dose of 1U of insulin per kg of body weight per day. A composite diabetes 
medication score was calculated as the sum of each medication score.  
Insulin and glucose kinetics after mixed meal ingestion and over 24 hours. The insulin secretion 
rate was determined by using a stochastic deconvolution of the plasma C-peptide concentration.15-17 
The clearance rate of insulin was calculated as the ratio of the insulin secretion rate to the prevailing 
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plasma insulin concentration. The 4-hour postprandial and 24-hour area under the curves for plasma 
glucose, free fatty acid, C-peptide, insulin, and insulin secretion rate were calculated by using the 
trapezoid method. Total (endogenous and meal-derived) glucose rate of appearance, ingested glucose 
rate of appearance, and endogenous glucose rate of appearance were calculated as previously 
described.4  
Multiorgan insulin sensitivity. Hepatic insulin sensitivity (suppression of glucose rate of 
appearance into the systemic circulations) and adipose tissue insulin sensitivity (suppression of 
palmitate rate of appearance into the systemic circulations) was calculated during stages 1 and 2 of the 
hyperinsulinemic-euglycemic pancreatic clamp procedure, and skeletal muscle insulin sensitivity 
(stimulation of glucose rate of disappearance from the systemic circulations) was calculated during 
stage 3 of the clamp procedure as previously described.2 Whole-body insulin sensitivity was calculated 
as the glucose infusion rate during stage 3 of the clamp procedure relative to prevailing plasma insulin 
concentrations.  
β-cell function. β-cell function was assessed as the product of β-cell glucose sensitivity (the ratio 
of postprandial total areas-under-the-curve of insulin secretion rate to total areas-under-the-curve of 
postprandial plasma glucose) and whole-body insulin sensitivity (glucose infusion rate divided by the 
plasma insulin concentration during stage 3 of the clamp procedure).4,7 
Statistical Analyses 
The difference in the treatment response between the Diet and Surgery groups was evaluated by using 
analysis of covariance with the post-intervention value as the dependent variable, the study group as 
the independent variable, and the baseline value as the covariate. Because the two groups were well-
matched on potential confounding variables, no additional covariates were included. The adequacy of 
the fit of all models was evaluated by assessing regression residuals (Table S1-3). A p-value ≤ 0.05 
was considered statistically significant for the single predefined primary outcome (hepatic insulin 
sensitivity). All other (secondary) outcomes should be regarded as exploratory, therefore only the 95% 
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confidence intervals are provided for statistical inference. The within-group change in each outcome 
was evaluated by determining the mean and 95% confidence interval of the difference between the pre- 
and post-intervention values, which were estimated by using paired t-tests. Statistical analysis was 
performed by using SPSS version 23 (IBM SPSS, Chicago, IL). 
Participants and Study Design  
Thirty-three men and women with obesity and type 2 diabetes were enrolled in this study. 
Eighteen participants were enrolled in the low-calorie diet (Diet) group and 15 participants scheduled to 
have Roux-en-Y gastric bypass surgery at Barnes-Jewish Hospital (St. Louis, Missouri, USA) were 
enrolled in the Surgery group (Supplemental Figure 1 CONSORT Diagram). Four participants in the 
Diet group dropped out of the study (2 before starting the weight loss intervention, and 2 during the 
weight loss intervention) and 3 were withdrawn because they were unable to achieve the minimum 
targeted 16% weight loss. Four participants in the Surgery group dropped out of the study before 
surgery. Accordingly, 11 participants in the Diet and Surgery groups completed the study. All 
participants completed a comprehensive screening evaluation consisting of medical history and 
physical examination, a resting electrocardiogram, and standard blood tests. Eligibility criteria was used 
to determine eligibility for participation. All participants provided written informed consent before 
participating in this study, which was approved by the Institutional Review Board of Washington 
University School of Medicine in St. Louis, MO. 
Study Eligibility Criteria 
All participants met the following eligibility criteria:  
Inclusion criteria: 1) men and women aged 25 to 65 years, inclusive at the time of informed 
consent; 2) body mass index between 34.0 and 55.0 kg/m2 ; 3) diagnosis of type 2 diabetes based on 
HbA1C >6.5%, results of oral glucose tolerance test or medical history plus current use of anti-diabetes 
medications; 4) scheduled for Roux-en-Y gastric bypass surgery at Barnes-Jewish Hospital (Saint 
Louis, Missouri, USA) for Surgery group participants; and 5) provided written informed consent.   
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Exclusion criteria: 1) evidence of significant organ system dysfunction (e.g., severe pulmonary 
or kidney disease) or a disease that could affect the study outcome measures other than obesity and 
type 2 diabetes, or significantly increase the risk of the study procedures; 2) cancer or cancer that has 
been in remission for <5 years; 3) previous intestinal resection; 4) regular use of tobacco products; 5) 
use of medication that can affect the study outcome measures; 5) regular exercise for more than 90 
minutes per week; 6) women who are pregnant or lactating; 6) conditions that render subject unable to 
complete all testing procedures (e.g. aversion to needles, metal implants that prevent magnetic 
resonance imaging); 7) persons unable or unwilling to follow the study protocol; and 8) persons not able 

































Figure S2.  
Effect of weight loss on plasma branched-chain amino acids, C3 and C5 acylcarnitines and bile acids, 
and the composition of the gut microbiome in the Diet and Surgery groups.    
 
A, plasma branched-chain amino acids and B, C3/C5 acylcarnitines measured serially for 24 hours 
(gray bars represent time of meal consumption) and C, their respective 24-hour areas-under-the-curve 
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before and after weight loss induced by low-calorie diet (Diet, n=11) or Roux-en-Y gastric bypass 
(Surgery, n=7). The effect of weight loss on the 24-hour pattern of plasma branched-chain amino acids 
and C3/C5 acylcarnitines were different between groups, manifested by higher peaks in plasma 
branched-chain amino acids and C3/C5 acylcarnitine concentrations early after meal ingestion, 
followed by rapid reductions in circulating levels and lower plasma areas-under-the-curves after weight 
loss in the Surgery group than the Diet group. The ANCOVA-derived mean post-weight loss group 
difference is -0.34 (-0.16 to -0.05, 95% confidence interval) for branched-chain amino acids and  
-0.46 (-0.66 to -0.27, 95% confidence interval) for C3/C5 acylcarnitines. Plotted values are the mean ± 
SEM. D, total fasting plasma bile acids concentrations before and after weight loss in the Diet (n=11) 
and Surgery (n=9) groups. Post-weight loss values were higher in the Surgery group than the Diet 
group; ANCOVA-derived mean post-weight loss group difference is 0.76 (0.11 to 1.42, 95% confidence 
interval). E left, principal coordinates analysis of Bray-Curtis dissimilarity of sub-operational taxonomic 
units in the Diet (gray) and Surgery (blue) groups before and after weight loss; labels are group means 
and segments are the distance to individual samples. E middle, relative change in gut microbial phyla 
after weight loss in the Diet (black) and Surgery (blue) groups; values are the mean change within each 
group ± 95% confidence interval estimated by using negative binomial regression. E right, gut microbial 
genera that changed differently after weight loss induced by Surgery than Diet (Group by Time 
interaction false discovery rate <0.05). *Value after weight loss significantly different (false discovery 
rate <5%) from value before weight loss. Sample sizes for stool microbiome analyses are n=10 in the 
Diet and n=9 in the surgery groups. Abbreviations: AUC, areas-under-the-curve; PCoA, principal 
coordinates analysis.  
16 
 



















*Diet group was coded as the reference in the treatment group coefficient.  
Intercept, beta coefficient relating the Before value (the covariate) to the After value, and the treatment 
group beta coefficient (the estimated difference between the mean After value in the Surgery group 
relative to the After value in the Diet group). To convert the values for glucose to millimole per liter, 
multiply by 0.05551. To convert the values for insulin to picomole per liter, multiply by 6.0. To convert 
the values for free fatty acid to grams per liter, multiply by 0.01.  
Variables Intercept 
Coefficient of 





Body weight (kg) 4.77 0.782 -1.09 
Body mass index (kg/m2) 1.44 0.788 -0.392 
Fat mass (kg) -3.95 0.793 0.579 
Body fat (%) -11.3 1.11 0.998 
Fat free mass (kg) -0.508 0.932 -1.32 
Intra-abdominal adipose tissue volume (cm3) -85.0 0.681 157 
Intrahepatic triglyceride content (%) 2.09 0.132 1.43 
Free fatty acids (mg/dl) 7.93 0.371 -0.851 
Glucose (mg/dl) 76.5 0.186 0.768 
Insulin (μU/ml) 9.56 0.119 -3.48 
HbA1c (%) 4.81 0.097 0.517 
High molecular weight adiponectin (μg/ml) 0.937 0.754 0.072 
Leptin (ng/l) 5.34 0.384 -8.53 
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Table S2. Remaining Regression Output from Analysis of Covariance Related to Table 2 
*Diet group was coded as the reference in the treatment group coefficient.   
Intercept, beta coefficient relating the Before value (the covariate) to the After value, and the treatment 
group beta coefficient (the estimated difference between the mean After value in the Surgery group 
relative to the After value in the Diet group). To convert the values for C-peptide to nanogram per 
milliliter, multiply by 0.331. Abbreviations: AUC, area-under-the-curve; FFM, fat-free mass; Ra, rate of 









4-h meal glucose AUC (mg/dl × min × 103) 15.1 0.332 8.56 
4-h meal insulin AUC (μU/ml × min × 103) 6.86 0.246 1.34 
Total glucose Ra 4-h AUC (μmol/kg FFM/min × min) 2540 0.472 138 
Ingested glucose Ra 4-h AUC (μmol/kg FFM/min × min) 2030 0.498 -19.1 
Endogenous glucose Ra 4-h AUC (μmol/kg FFM/min × min) 1390 0.077 159 
24-h glucose AUC (mg/dl × min × 103) 96.9 0.233 32.3 
24-h free fatty acid AUC (mg/dl × min× 103) 4.59 0.448 2.67 
24-h insulin AUC (μU/ml × min × 103) 27.1 0.218 1.47 
24-h insulin secretion rate AUC (pmol/min × 103) 245 0.568 -31.4 
24-h insulin clearance rate (L/min) 1.80 0.516 0.114 
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Table S3. Remaining Regression Output from Analysis of Covariance Related to Table 3 
*Diet group was coded as the reference in the treatment group coefficient.   
Intercept, beta coefficient relating the Before value (the covariate) to the After value, and the treatment 
group beta coefficient (the estimated difference between the mean After value in the Surgery group 
relative to the After value in the Diet group). Abbreviations: FFM, fat-free mass; Ra, rate of appearance 
into the systemic circulation; Rd, rate of disposal from the systemic circulation. 
Variables Intercept 
Coefficient of 





Glucose Ra (Stage 1) (μmol/kg FFM/min) 3.89 0.360 0.252 
Glucose Ra (Stage 2) (μmol/kg FFM/min) 2.61 0.095 0.021 
Glucose Rd (Stage 3) (μmol/kg FFM/min) 47.4 0.465 -6.51 
Palmitate Ra (Stage 1) (μmol/kg FFM/min) 0.659 0.084 0.327 
Palmitate Ra (Stage 2) (μmol/kg FFM/min) 0.507 0.124 -0.044 
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